Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Theravance Biopharma (TBPH) Non-Current Assets (2016 - 2025)

Theravance Biopharma (TBPH) has disclosed Non-Current Assets for 13 consecutive years, with $67.1 million as the latest value for Q4 2025.

  • Quarterly Non-Current Assets fell 65.24% to $67.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $380.9 million through Dec 2025, down 58.7% year-over-year, with the annual reading at $67.1 million for FY2025, 65.24% down from the prior year.
  • Non-Current Assets for Q4 2025 was $67.1 million at Theravance Biopharma, up from $60.8 million in the prior quarter.
  • The five-year high for Non-Current Assets was $277.2 million in Q1 2023, with the low at $37.7 million in Q4 2021.
  • Average Non-Current Assets over 5 years is $176.0 million, with a median of $199.7 million recorded in 2022.
  • The sharpest move saw Non-Current Assets skyrocketed 573.66% in 2022, then crashed 75.39% in 2025.
  • Over 5 years, Non-Current Assets stood at $37.7 million in 2021, then surged by 573.66% to $253.9 million in 2022, then decreased by 2.16% to $248.5 million in 2023, then fell by 22.28% to $193.1 million in 2024, then crashed by 65.24% to $67.1 million in 2025.
  • According to Business Quant data, Non-Current Assets over the past three periods came in at $67.1 million, $60.8 million, and $59.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.